HUTCHMED Reports Strong H1 2025 Financial Results, Approvals, and Pipeline Progress

HUTCHMED reports a net income of $455 million for H1 2025, driven by a $416.3 million divestment gain. ORPATHYS gains China approval for a major lung cancer indication, triggering an $11 million milestone payment from AstraZeneca. HUTCHMED's cash position strengthened to $1.36 billion as of June 30, 2025. In-market sales of FRUZAQLA increased by 25%, while ELUNATE declined due to competitive pressures. The company plans to advance new ATTC platform drug candidates into clinical development by late 2025.

HUTCHMED (China) Limited ("HUTCHMED") has released its financial results for the first half of 2025, highlighting significant growth and strategic advancements. The company reported a net income of $455.0 million, largely driven by a $416.3 million divestment gain from the disposal of a partial equity stake in a non-core joint venture [1].

Key highlights from the report include:

1. Expansion and Approvals: HUTCHMED's ORPATHYS® (savolitinib) secured China approval for its third lung cancer indication for EGFRm NSCLC patients with MET amplification. This approval triggered an $11.0 million milestone payment from AstraZeneca, marking a significant milestone in the company's growth strategy [1].

2. Increased Cash Position: The company's cash balance as of June 30, 2025, stood at $1.36 billion, bolstered by the divestment gain and strong operational performance [1].

3. Sales Performance: In-market sales of FRUZAQLA® increased by 25% to $162.8 million, reflecting strong global expansion. However, in-market sales of ELUNATE® declined due to competitive pressures, resulting in a 4% decrease in total in-market sales [1].

4. Pipeline and Development: HUTCHMED plans to advance multiple new drug candidates from its Antibody-Targeted Therapy Conjugates (ATTC) platform into clinical development by late 2025. The company aims to leverage its 20 years of experience in drug discovery and development to bring innovative medicines to market [1].

5. Regulatory Updates: The company reported several regulatory milestones, including the approval of savolitinib for 2L EGFRm NSCLC patients with MET amplification in combination with TAGRISSO®, and the conditional approval of tazemetostat for 3L R/R follicular lymphoma with EZH2 mutation [1].

In conclusion, HUTCHMED's first-half 2025 results demonstrate robust financial performance and strategic progress. The company's focus on pipeline expansion, regulatory milestones, and strategic partnerships positions it well for continued growth in the coming quarters.

References:
[1] https://www.hutch-med.com/2025-half-year-results/